ESR1 Mutations as Essential Markers for Understanding Endocrine Therapy Resistance in ER+ Metastatic Breast Cancer

Healthcare > Pharmaceutical3/20/2024 2:00 PM

Go to Registration Page


Oestrogen receptor 1 (ER/ESR1) mutations have arisen as crucial biomarkers for endocrine therapy resistance in ER positive metastatic breast cancer. Detecting these mutations is key for understanding acquired resistance during treatment.

APIS will be joined by SensID GmbH to deliver this FREE educational webinar on ESR1 mutations and the importance of their accurate and sensitive detection.

Gain insights into: - ESR1 mutations significance in breast cancer and their role in endocrine therapy resistance - APIS ESR1 Mutations Kit, an accessible method to detect ESR1 mutations - SensID ESR1 reference set to ensure accurate detection of mutations in cell-free DNA (cfDNA)

Have your questions answered by experts in gene mutation assay development and validation!


Rate This Webinar

community rating (0 votes): 
Rate or Review This Webinar


APIS Assay Technologies Ltd

APIS Assay Technologies Ltd

APIS Assay Technologies is leveraging systems biology, interrogating multi-OMICs biodata, and deploying innovative 'Clickmer' ligand binding technology, for the validation and translation of biomarker and therapeutic assets into clinical utility. They have deep expertise and capabilities in IVD development of molecular & immune-assays for ultimate product realization as diagnostic tests. Their mission is to enable faster, accurate prediction and prevention of disease, driven by the ambition to improve human health. APIS Assay Technologies is committed to realizing the clinical potential of systems biology and medicine in the diagnosis and personalization of treatment. Their products include the Breast Cancer Subtyping Kit, ESR1 Mutations Kit, Precision Expression Assays, SARS-CoV-2 IgG ELONA Kit, and SARS-CoV-2 IgG ELISA Kit. They also offer services such as contract assay development, clinical compliance services, contract manufacturing, and bioinformatics & software development.